Search

Your search keyword '"Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147)"' showing total 154 results

Search Constraints

Start Over You searched for: Author "Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147)" Remove constraint Author: "Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147)"
154 results on '"Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147)"'

Search Results

1. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014

2. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer

3. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

4. O-015 Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status

5. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

6. Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level

7. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone

8. Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank

9. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness

10. Sulfheme formation during homocysteine S-oxygenation by catalase in cancers and neurodegenerative diseases

11. Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial

12. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy

13. Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients

14. DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer

15. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab

16. A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney

17. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker

18. Routine molecular profiling of cancer: results of a one-year nationwide program of the French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients

19. Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype

20. Etat des lieux des tests RAS chez les patients atteints de cancer colorectal métastatique en 2014

21. New cellular mechanisms of gap junction degradation and recycling

22. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

23. Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies

24. FLASH-RAS : Etat des lieux des tests RAS chez des patients atteint d’un cancer colorectal métastatique en 2014

25. Review of the current status of RAS mutation testing in patients with metastatic colorectal cancer (mCRC): Flash-RAS study

26. Kidney Transplant Recipients Carrying the CYP3A4*22 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

27. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

28. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status

29. Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France

30. Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells

31. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011

32. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience

33. Colonization-Induced Host-Gut Microbial Metabolic Interaction

34. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

35. Loss of SMARCB1 expression in colon carcinoma

36. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

37. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study

38. Microfluidic extraction and digital quantification of circulating cell-free DNA from serum

39. HPV-circulating tumoural DNA by droplet-based digital polymerase chain reaction, a new molecular tool for early detection of HPV metastatic anal cancer? A case report

40. Development and validation of a UPLC-UV method for the quantification of thiopurine methyltransferase enzyme activity in human erythrocytes

41. Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays

42. Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

43. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma

44. Streamlined digital bioassays with a 3D printed sample changer

45. Beyond the on/off chip trade-off: A reversibly sealed microfluidic platform for 3D tumor microtissue analysis

46. Development of molecular analyzes by digital PCR for clinical practice: positioning, current applications and perspectives

47. BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA

48. High throughput single cell counting in droplet-based microfluidics

49. VARIANT ALLELIC FREQUENCY IN ADULTS WITH BRAF MUTATED HISTIOCYTOSES AND RESPONSE TO BRAF INHIBITORS

50. CUTANEOUS ADVERSE EVENTS IN CHILDREN TREATED WITH BRAF-INHIBITOR VEMURAFENIB FOR REFRACTORY BRAF (V600E) MUTATED LANGERHANS CELL HISTIOCYTOSIS: A EUROPEAN COHORT STUDY

Catalog

Books, media, physical & digital resources